Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0LRYJX |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Antibody 2 |
|||||
| Synonyms |
Antibody 2
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG1 |
|||||
| Antigen Name | Syndecan-1 (SDC1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Varible Domain |
QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIY
NEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTV SS Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
NYWIE
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
EILPGTGRTIYNEKFKG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
RDYYGNFYYAMDY
Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQMTQSTSSLSASLGDRVTISCSASQGINNYINWYQOKPDGTVELLIYYTSTLOSGVPS
RFSGSGSGTDYSLTISNLEPEDIGTYYCOOYSKLPRTFGGGTKLEIK Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
SASQGINNYLN
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
YTSTLQS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQYSKLPRT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
wO2024181570A1 ADC2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 0% | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
|
||||
| In Vivo Model | Capan-1 derived Xenograft Model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 7% | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
|
||||
| In Vivo Model | Capan-1 derived Xenograft Model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 70% | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
|
||||
| In Vivo Model | Capan-1 derived Xenograft Model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
248 ng/mL
|
Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1000 cells/well of Capan-1 in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
274 ng/mL
|
Negative CD138 expression (CD138-) | ||
| Method Description |
1000 cells/well of Jurkat in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||